total revenue vs ahead consensu though non-gaap ep
vs due cog charg relat harvoni product sale guidanc
y/i impli rel stabl product revenu think
under-valued cash flow though major re-rat requir pipelin
program capabl drive revenu growth
world-wide hiv sale q/q y/i consensu
hcv sale q/q y/i
consensu strength hiv sale brought product sale
q/q y/i ahead estim revenu
q/q y/i beat estim consensu gilead
report non-gaap gross margin vs lower non-gaap gross margin
due one-tim reserv charg primarili excess harvoni inventori due
shift demand toward epclusa non-gaap sg expens
revenu revenu vs
respect non-gaap ep q/q y/i significantli consensu
cog charg reduc non-gaap ep
gilead guid total product sale y/i includ
growth hiv y/i midpoint declin
hcv revenu y/i midpoint gilead estim loss exclus
letairi ranexa repres headwind product sale gilead
product sale guidanc bracket prior estim suggest rel
stabl product revenu gilead guid non-gaap gross margin vs
non-gaap expens vs sg expens
vs effect tax rate vs
adjust estim consist notabl product sale estim
increas though project non-gaap ep estim
decreas dcf-base price target remain
hiv sale q/q y/i consensu
 hiv revenu q/q y/i grow robustli continu
benefit biktarvi launch biktarvi revenu third full quarter
 market make fastest hiv launch yet biktarvi number one
prescrib regimen treatment-na switch patient consult
consid biktarvi go-to regimen demand trend gilead franchis overal
remain healthi prescript q/q gilead report taf-bas regimen
account gilead hiv prescript volum
end sale intern market q/q y/i
impact avail truvada gener sever european countri biktarvi
approv eu june launch well germani franc launch
spain itali anticip mid-year gilead expect launch
biktarvi across europ help off-set impact gener possibl return
growth
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t oncolog
platform kite expect combin launch new taf-bas
combin pill hiv market growth share gain price increas hiv franchis
sale remain stabl despit viread patent expir gilead hcv
franchis struggl declin patient volum erod sale project gilead hcv
franchis gener world-wide sale declin expect
partial off-set pipelin program includ yescarta filgotinib base dcf
analysi gilead stock under-valued expect cash flow
data filgotinib
data selonsertib stellar trial
data selonsertib stellar trial
descovi discov trial
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv fungal infect
acquir car-t oncolog platform kite gilead antivir portfolio biggest
revenu driver gilead lead hiv franchis anchor tenofovir well-toler
efficaci nucleotid analog gilead develop sever tenofovir-bas
biktarvi togeth captur share treatment-na hiv patient
drive hiv franchis revenu project revenu
hcv franchis led sofosbuvir nucleosid inhibitor result phase trial
sofosbuvir-bas regimen shown potent well toler high
barrier viral resist expect hcv franchis maintain approx
revenu
 hcv revenu q/q y/i ex-u hcv revenu
q/q y/i declin global declin q/q acceler compar
q/q manag remain hope stabl predict busi
go forward slow steadi declin hcv market patient start gilead newli
launch subsidiari begun offer author gener epclusa
harvoni gilead expect gener reduc patient cost expand access
begin grow market share medicaid market hcv
estim decreas slighlti
gilead record q/q revenu yescarta fourth full quarter
market consensu estim cancer
center author treat patient eu vs prior guidanc
new center continu author focu shift increas
patient flow part via educ effort commun oncologist direct patient
author center gilead anticip adopt gradual improv center
gain experi
yescarta approv eu august gilead treat commerci
patient germani activ site franc anticip
european approv yescarta gilead previous leas manufactur facil
netherland come on-lin full year revenu yescarta
gilead guid increment impli nearli doubl
revenu compar launch continu ramp yescarta
expand european market
clinic trial yescarta continu pivot phase studi line dlbcl
phase ii studi combin initi pivot
phase ii yescarta r/r indol nhl complet enrol
addit gilead expect file fda approv formerli
construct yescarta differ manufactur mcl
complet enrol pivot phase ii adult
took impair charg bcma car-t program develop
continu expect file ind allogen car-t therapi
gilead also highlight recent progress pipelin develop inflamm sever
phase studi filgotinib on-going rheumatoid arthriti ulcer coliti
crohn diseas septemb filgotinib succeed phase finch trial ra
patient inadequ respons dmard addit phase trial ra
fulli enrol data readout expect
enrol difficult treat popul think de-risk filgotinib
trial phase ii studi filgotinib sever inflammatori diseas
result selonsertib stellar stellar phase nash
anticip respect stellar ident design
except stellar enrol patient bridg fibrosi baselin
stellar enrol patient compens cirrhosi fibrosi gilead expect
studi posit file regulatori approv success
could first bring product nash market specialist poll cowen
confer gave stellar chanc succeed
even slightli less optimist stellar panelist agre stellar better
odd success particularli given hard know long patient live
stage diseas therefor degre qualiti scar organ
gilead also plan releas data descovi phase discov trial hiv
prophylaxi
investor wait gilead revenu stabil two year declin
gilead guidanc impli product sale growth suggest
overal gilead busi final plateau expect gilead hcv busi
continu contract becom rel minor part gilead top-lin
launch taf regimen gilead hiv franchis continu
bright spot anticip y/i growth appear capabl compens
hcv trend well loss exclus letairi ranexa therefor day
precipit declin gilead revenu appear past gilead continu
under-valued project cash flow dcf-base price target remain
nonetheless hiv franchis also face patent expiri next sever
year gilead prospect long-term top-lin growth appear middl fact project
product sale compound-annual-growth-rate therefor suspect major re-rat like
requir visibl pipelin candid capabl drive meaning reacceler
gilead develop market treatment hiv hbv hcv fungal infect
gilead antivir portfolio largest revenu driver next sever
year gilead lead hiv franchis anchor tenofovir well-toler
gener revenu captur share patient newli initi
hiv therapi tenofovir disoproxil fumar viread lost patent
protect gilead develop second gener version tenofovir
alafenamid taf improv safeti extend patent protect
project sale gilead hiv franchis grow
launch new patent-protect combin pill biktarvi bic/f/taf
genvoya e/c/f/taf descovi f/taf odefsey e/r/taf taf
regimen extend commerci life franchis howev expiri
 patent protect truvada complera model hiv sale
declin y/i gilead hcv franchis built around
sovaldi nucleosid inhibitor whose potenc high barrier resist
made cornerston market-lead all-or hcv combin sovaldi
launch decemb eu januari approv
gilead harvoni sofosbuvir ledispavir octob brought first
fda-approv interferon free regimen genotyp hcv patient largest
hcv popul hcv franchis got fast start post
revenu unfortun best day gilead hcv
franchis past emerg competit gild hcv franchis
gener revenu estim continu declin
gilead recent expand oncolog franchis
acquisit kite gilead gain yescarta car-t therapi anhl
approv fda octob well lead car-t
platform cowen project yescarta achiev revenu third line anhl
hope gilead trough earn final sight
two year rapid declin hcv revenu project non-gaap ep
ep stabl gilead current trade
forward pe project cash flow yield base
dcf analysi gilead stock under-valued expect cash flow
data phase selonsertib nash stellar
complet enrol filgotinib select phase studi uc
data filgotinib finch studi ra
data filgotinib finch studi ra
primari endpoint data phase discov trial descovi prep
data phase studi selonsertib nash stellar
initi phase studi cilofexor psc
data phase ii studi hbv
complet enrol pivot phase ii adult zuma
complet phase studi vesatolimod hiv cure
data phase ib studi capsid inhibitor
data phase ii studi nrti
initi phase studi selonsertib diabet kidney diseas
data phase ii cutan lupu erythematosu
data phase ii sjogern syndrom
initi phase ii studi uc
complet enrol phase line dlbcl zuma
initi phase ii combin studi yescarta rituximab lenalidomid zuma
file fda approv mcl zuma
file ind allogen
data phase iib atla combin studi nash
complet enrol phase ii remdesivir ebola survivor
complet enrol ph ia mage solid tumor
data filgotinib select phase studi uc
complet enrol filgotinib divers phase studi crohn diseas
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest net income/ loss incom loss attribut non-controlling net fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
financi year growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
